Berry Wealth Group LP Acquires New Holdings in Edwards Lifesciences Co. (NYSE:EW)

Berry Wealth Group LP acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,059 shares of the medical research company’s stock, valued at approximately $386,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 0.6% during the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock worth $3,577,163,000 after purchasing an additional 325,808 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Edwards Lifesciences by 9.2% during the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock worth $1,138,575,000 after purchasing an additional 1,390,427 shares in the last quarter. Brown Advisory Inc. lifted its position in shares of Edwards Lifesciences by 5.7% during the third quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock worth $1,048,424,000 after purchasing an additional 818,849 shares in the last quarter. Northern Trust Corp lifted its position in shares of Edwards Lifesciences by 3.9% during the third quarter. Northern Trust Corp now owns 6,357,473 shares of the medical research company’s stock worth $440,446,000 after purchasing an additional 241,347 shares in the last quarter. Finally, WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its position in shares of Edwards Lifesciences by 16.8% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,100,000 shares of the medical research company’s stock worth $312,625,000 after purchasing an additional 590,000 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EW has been the topic of several research reports. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. Citigroup raised their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. Evercore ISI reduced their target price on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a report on Friday, April 26th. Piper Sandler raised their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a report on Friday, April 26th. Finally, OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $92.71.

Edwards Lifesciences Stock Performance

Shares of EW traded down $0.38 during mid-day trading on Wednesday, reaching $84.29. 936,853 shares of the company’s stock were exchanged, compared to its average volume of 3,795,339. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The stock has a market capitalization of $50.74 billion, a PE ratio of 36.50, a price-to-earnings-growth ratio of 3.62 and a beta of 1.05. The business’s fifty day simple moving average is $90.23 and its 200-day simple moving average is $79.16. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Catherine M. Szyman sold 27,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, VP Catherine M. Szyman sold 27,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,715 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the sale, the vice president now directly owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The disclosure for this sale can be found here. Insiders sold a total of 201,254 shares of company stock valued at $17,788,304 over the last three months. 1.27% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.